1984-25-4

Usage

Uses

Used in Organic Synthesis:
4-BROMO-N-ETHYLBENZENESULPHONAMIDE is used as a building block in organic synthesis for the creation of various pharmaceuticals and agrochemicals. Its unique structure allows for the development of new compounds with specific properties and functions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-BROMO-N-ETHYLBENZENESULPHONAMIDE serves as a key intermediate in the synthesis of pharmaceuticals. Its presence in the molecular structure can contribute to the desired biological activity and therapeutic effects of the final drug product.
Used in Antimicrobial Applications:
4-BROMO-N-ETHYLBENZENESULPHONAMIDE has been investigated for its potential use as an antimicrobial agent. Its ability to inhibit the growth of microorganisms makes it a promising candidate for the development of new antibiotics and antifungal agents.
Used in Antitumor Applications:
4-BROMO-N-ETHYLBENZENESULPHONAMIDE has also been explored for its potential as an antitumor agent. Its ability to interfere with the growth and proliferation of cancer cells could lead to the development of novel anticancer drugs.
Used in Pharmaceutical Industry:
4-BROMO-N-ETHYLBENZENESULPHONAMIDE is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique chemical properties enable the development of innovative medications with improved efficacy and safety profiles.
Used in Agrochemical Industry:
In the agrochemical industry, 4-BROMO-N-ETHYLBENZENESULPHONAMIDE is utilized as a building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these products can enhance their effectiveness in controlling pests and weeds, ultimately contributing to increased crop yields and food security.

InChI:InChI=1/C8H10BrNO2S/c1-2-10-13(11,12)8-5-3-7(9)4-6-8/h3-6,10H,2H2,1H3

Upstream product

• 75-04-7 ethylamine 
• 557-66-4 ethanamine hydrochloride 
• 98-58-8 4-bromobenzenesulfonyl chloride 

Downstream Products

• 871329-65-6 4-(N-ethylsulfamoyl)phenylboronic acid 
• 1572928-47-2 benzyl 4-(4-(ethylsulfamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinecarboxylate 
• 1572927-73-1 4-(2S)-(4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)-N-ethylbenzenesulfonamide 
• 1572927-74-2 4-(2R)-(4-((6-amino-3-pyridinyl)sulfonyl)-2-(1-propyn-1-yl)-1-piperazinyl)-N-ethylbenzenesulfonamide 
• 1572928-49-4 tert-butyl (5-((4-(4-(ethylsulfamoyl)phenyl)-3-(1-propyn-1-yl)-1-piperazinyl)sulfonyl)-2-pyridinyl)carbamate 
• 1572928-48-3 N-ethyl-4-(2-(1-propyn-1-yl)-1-piperazinyl)benzenesulfonamide 
• 936728-18-6 4-bromo-N-ethylbenzenesulfonamide 
• 56059-56-4 N-Ethyl-N-thallium(I)-4-bromphenylsulfonamid 

Relevant academic research and scientific papers

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration

Currently, the therapeutic options for treatment of liver failure are very limited. As mitogen-activated protein kinase kinase 4 (MKK4) has recently been identified by in vivo RNAi experiments to be a major regulator in hepatocyte regeneration, we pursued the development of a small molecule targeting this protein kinase. Starting from the approved BRAFV600E inhibitor vemurafenib (8), that showed a high off-target affinity to MKK4 in an initial screening, we followed a scaffold-hopping approach, changing the core heterocycle from 1H-pyrrolo[2,3-b]pyridine to 1H-pyrazolo[2,3-b]pyridine (10). Affinity to MKK4 could be conserved while the selectivity against off-target protein kinases was slightly improved. Further modifications led to 58 and 59 showing high affinity to MKK4 in the low nanomolar range and excellent selectivity profile from mandatory multiparameter-optimization for the essential anti-targets (MKK7, JNK1) and off-targets (BRAF, MAP4K5, ZAK) in the MKK4 pathway. Herein we report the first selective MKK4 inhibitors in this class.

PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH

The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to tricyclic alkyne compounds of formula I that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where gluco

Copper-catalyzed trifluoromethylation and cyclization of aromatic-sulfonyl-group-tethered alkenes for the construction of 1,2-benzothiazinane dioxide type compounds

A multi-talented system: An efficient copper-catalyzed tandem trifluoromethylation/annulation of an electron-deficient aromatic ring has been developed. This method provides a powerful and straightforward way to synthesize trifluoromethylated 1,2-benzothiazinane dioxides under mild conditions (see scheme). The mechanism was investigated by a series of kinetic experiments and isotopic labeling studies.

ARYL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR

In one embodiment, compounds of the following structure are described, wherein R1 to R7 are described herein. Also provided are methods for preparing these compounds and methods of contraception; treating or preventing fibroids; trea